EVOO and Metabolic Liver Health in MASLD

MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and other cardio-metabolic risk factors. Lifestyle modification, particularly through the Mediterranean Diet, is the first-line intervention, and extra virgin olive oil is a key component thanks to its monounsaturated fatty acids and bioactive compounds with anti-inflammatory and antioxidant effects. Several studies indicate that extra virgin olive oil supplementation, especially within a Mediterranean Diet pattern, reduces hepatic steatosis, improves inflammation, oxidative stress, and glucose and lipid profiles, and may promote weight loss and reduction of fat mass, also through potential effects on the gut microbiota. EFSA recognizes protective effects with a daily intake of at least 20 g of extra virgin olive oil, but it is still unclear whether this amount is optimal for individuals with MASLD, particularly those who are overweight or obese

NCT Number	NCT07412444
Lead Sponsor	Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Conditions	MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Overweight
Enrollment	60 participants
Start Date	2026-05-06
Primary Completion	2027-05-06 (estimated)
Study Completion	2028-05-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-06